November 20, 2018
A Tokai Pharmaceuticals Inc. investor is fighting to keep alive a $10.8 million suit alleging that the company failed to disclose that too few research subjects were left to yield meaningful results in testing of a prostate cancer drug, arguing that the underwriters are liable for misstatements in Tokai investment documents.